The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Genome Editing Market Size Was Valued at USD 7.39 Billion in 2023, and is Projected to Reach USD 30.78 Billion by 2032, ...

AmpliTech Inc, the core division of AmpliTech Group, founded in 2002, Amplitech Inc, has proprietary low noise technology ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Flashpoint Therapeutics, a clinical-stage therapeutics company pioneering structural nanomedicine, today announced significant expansion of its therapeutic pipeline through strategic acquisitions and ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...